BR0314182A - Formulações compreendendo um composto de indolinona - Google Patents

Formulações compreendendo um composto de indolinona

Info

Publication number
BR0314182A
BR0314182A BR0314182-9A BR0314182A BR0314182A BR 0314182 A BR0314182 A BR 0314182A BR 0314182 A BR0314182 A BR 0314182A BR 0314182 A BR0314182 A BR 0314182A
Authority
BR
Brazil
Prior art keywords
formulations
indolinone
indolinone compound
compound
formulation
Prior art date
Application number
BR0314182-9A
Other languages
English (en)
Inventor
Paolo Gatti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31994326&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314182(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0314182A publication Critical patent/BR0314182A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"FORMULAçõES SóLIDAS COMPREENDENDO UM COMPOSTO DE INDOLINONA". A presente invenção descreve formulações de indolinonas. A formulação é adequada para administração parenteral ou oral, onde a formulação compreende uma indolinona, e um veículo farmaceuticamente aceitável por conseguinte. As formulações e os compostos dos mesmos são úteis para o tratamento de distúrbios relacionados com cinase de proteína.
BR0314182-9A 2002-09-10 2003-09-10 Formulações compreendendo um composto de indolinona BR0314182A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42113302P 2002-09-10 2002-09-10
PCT/IB2003/005293 WO2004024127A2 (en) 2002-09-10 2003-09-10 Solid formulations comprising an indolinone compound

Publications (1)

Publication Number Publication Date
BR0314182A true BR0314182A (pt) 2005-08-09

Family

ID=31994326

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314182-9A BR0314182A (pt) 2002-09-10 2003-09-10 Formulações compreendendo um composto de indolinona

Country Status (31)

Country Link
US (1) US20040229930A1 (pt)
EP (1) EP1536783B2 (pt)
JP (1) JP2006503032A (pt)
KR (1) KR20050059170A (pt)
CN (1) CN1688304A (pt)
AR (1) AR041193A1 (pt)
AT (1) ATE403425T1 (pt)
AU (1) AU2003280108B2 (pt)
BR (1) BR0314182A (pt)
CA (1) CA2498415C (pt)
DE (1) DE60322720D1 (pt)
DK (1) DK1536783T3 (pt)
DO (1) DOP2003000708A (pt)
ES (1) ES2309363T5 (pt)
GT (1) GT200300193A (pt)
HN (1) HN2003000272A (pt)
MX (1) MXPA05002690A (pt)
MY (1) MY136767A (pt)
NL (1) NL1024261C (pt)
NO (1) NO20051670L (pt)
NZ (1) NZ538636A (pt)
PA (1) PA8581801A1 (pt)
PE (1) PE20040989A1 (pt)
PL (1) PL375978A1 (pt)
PT (1) PT1536783E (pt)
RU (1) RU2005110663A (pt)
SI (1) SI1536783T1 (pt)
TW (1) TW200418836A (pt)
UY (1) UY27969A1 (pt)
WO (1) WO2004024127A2 (pt)
ZA (1) ZA200501897B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033098A1 (en) 2003-10-02 2005-04-14 Pharmacia & Upjohn Company Llc Salts and polymorphs of a pyrrole-substituted indolinone compound
CA2622870A1 (en) * 2005-09-20 2007-03-29 Pfizer Products Inc. Dosage forms and methods of treatment using a tyrosine kinase inhibitor
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含***并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (en) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
EP2220071A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US20100310668A1 (en) * 2008-02-13 2010-12-09 Ratiopharm Gmbh Pharmaceutical compositions comprising n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide
EP2138167A1 (en) * 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
WO2010039798A2 (en) * 2008-09-30 2010-04-08 Teva Pharmaceutical Industries Ltd. Amorphous compositions of sunitinib base and l-malic acid
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CN103301116A (zh) * 2012-03-16 2013-09-18 大鹏药品工业株式会社 口服医药组合物
PE20142406A1 (es) 2012-05-04 2015-01-23 Pfizer Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
CN104069076A (zh) * 2013-03-29 2014-10-01 浙江九洲药业股份有限公司 一种无定型的舒尼替尼与pvp的组合物
PL3062815T3 (pl) 2013-11-01 2019-07-31 Pfizer Inc. Wektory do ekspresji antygenów związanych z gruczołem krokowym
WO2015110952A1 (en) 2014-01-21 2015-07-30 Wockhardt Limited Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
BR112021013383A2 (pt) * 2019-01-09 2021-09-14 Celgene Corporation Composições farmacêuticas compreendendo (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)benzil)piperazin-1-il)-3-fluorobenzonitrila e métodos para usar as mesmas
US20230355581A1 (en) * 2020-07-02 2023-11-09 The Board of Regents of the Unversity of Texas System Methods of treatment for melanoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
DE19956598A1 (de) * 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
WO2001060814A2 (en) * 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds

Also Published As

Publication number Publication date
PL375978A1 (en) 2005-12-12
TW200418836A (en) 2004-10-01
NZ538636A (en) 2006-04-28
NO20051670L (no) 2005-04-04
SI1536783T1 (sl) 2008-12-31
AR041193A1 (es) 2005-05-04
EP1536783A2 (en) 2005-06-08
CA2498415A1 (en) 2004-03-25
EP1536783B1 (en) 2008-08-06
NL1024261C (nl) 2010-04-06
US20040229930A1 (en) 2004-11-18
AU2003280108A1 (en) 2004-04-30
ATE403425T1 (de) 2008-08-15
WO2004024127A2 (en) 2004-03-25
GT200300193A (es) 2004-04-29
PE20040989A1 (es) 2004-12-28
CN1688304A (zh) 2005-10-26
DK1536783T3 (da) 2008-10-13
NL1024261A1 (nl) 2004-03-11
MY136767A (en) 2008-11-28
HN2003000272A (es) 2008-07-29
DOP2003000708A (es) 2004-03-31
ES2309363T5 (es) 2011-12-07
UY27969A1 (es) 2004-04-30
EP1536783B2 (en) 2011-08-24
RU2005110663A (ru) 2005-09-10
AU2003280108B2 (en) 2007-04-05
ZA200501897B (en) 2005-09-07
DE60322720D1 (de) 2008-09-18
PT1536783E (pt) 2008-10-10
CA2498415C (en) 2007-05-29
PA8581801A1 (es) 2005-02-04
JP2006503032A (ja) 2006-01-26
WO2004024127A3 (en) 2004-06-03
ES2309363T3 (es) 2008-12-16
KR20050059170A (ko) 2005-06-17
MXPA05002690A (es) 2005-05-05

Similar Documents

Publication Publication Date Title
BR0314182A (pt) Formulações compreendendo um composto de indolinona
BR0313176A (pt) Composições de pirazol úteis como inibidores de gsk-3
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
GEP20053675B (en) Pyridazinone Aldose Reductase Inhibitors
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
BR0206955A (pt) Ligantes de receptores de canabinóides
NO20043367L (no) Oralt farmasoytisk preparat
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20062051L (no) Farmasoytisk virkestoffinneholdende formulering med belegg
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0113590A (pt) 7-oxo-piridopirimidinas
DE60001586D1 (de) Diphenyl-piperidin derivate
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
CA2535210A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2003051838A3 (en) Protein kinase inhibitors
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
HUP0004900A2 (hu) Mozgászavarok kezelésére szolgáló, hatóanyagként NMDA-receptor antagonista hatású piperidinszármazékokat tartalmazó gyógyszerkészítmények
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
SE9902938D0 (sv) Pharmaceutical compositions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 31/404, A61K 9/16, A61P 35/00

Ipc: A61K 31/404 (2011.01), A61K 9/16 (2011.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.